Empowered Patient Podcast

Greg Mayes, President and CEO of Reunion Neuroscience, is developing a psychedelic therapy for the treatment of postpartum depression. This serious acute, non-chronic mental health condition affects an estimated 20% of women after giving birth.  A phase two trial is underway to evaluate how RE-104, a rapid-acting psilocybin-like novel molecule, can help women with moderate to severe postpartum depression get faster relief compared to existing treatments. Greg explains, "The course of our psychedelic administration is significant because we believe it can be shorter in time period than other psilocybin-like treatments. In our case, we were able to establish it as 3.7 hours. Because it's a psychedelic and it is for an acute and non-chronic indication, we believe that women who take our product will see a rapid uptake and potentially day of administration benefit of the psychedelic therapy. Our phase two study is called the RECONNECT study because it's named for women reconnecting with themselves, their families, their children, and the world around them." "Postpartum depression is considered to be a subset depressive of major depressive disorder, major depressive order that's not put into remission after two treatments becomes treatment-resistant depression. There's also generalized anxiety disorder. We believe that RE104 and our lead product have a lot of legs to potentially go in this area. But as the CEO of the company, we want to stay focused. We know what we need to do first and foremost is we need to get our RECONNECT phase two proof of concept study and women with moderate to severe postpartum depression recruited. And we need to show that we can work there. Once we show that, we'll pivot to other indications. One is adjustment disorder in patients with cancer and with other major medical illnesses like Parkinson's disease, ALS, MS, or pulmonary fibrosis." #ReunionNeuro #PostPartumDepression #PPD #Psychedelics #Mothers #MentalHealth #Depression #RECONNECTStudy reunionneuro.com PPDReconnectstudy.com   Download the transcript here

Pedro Sanchez de Lozada, CEO of Canid, highlights the significant financial risks that pediatricians face in managing their vaccine inventory.  There are administrative burdens associated with ordering, patient demand, tracking, reporting, and filing for insurance reimbursement. The Canid platform was designed to be a vaccine-as-a-service model, removing risk and administrative work from pediatric practices, allowing small and independent practices to achieve economies of scale, and freeing up more time to spend with patients and their parents.  Pedro explains, "When managing a vaccine program, the expectation is that the pediatrician will buy and maintain the stock in their office until a patient comes in and gets vaccinated. So, the refrigeration, the temperature logging, the stocking up, and the cost of the vaccine always fall as liability to the pediatrician. And what happens there is that you have a fairly small margin on these vaccines. Now I'm sure we're going to get into this, but when people say pediatricians make money on vaccines, they're usually cherry-picking." "But in reality, as a pediatrician, you actually have to stock all the vaccines. And not all of them have decent margins. Some of them have negative margins. And so as a portfolio, you end up making a pretty thin margin, and then that doesn't even include all the different challenges you might have along the way. So let's take an example: a vaccine that expires or is dropped, and unfortunately needs to be wasted."   "So the way that we like to think about it is we want to make it so that the pediatrician can just give vaccines. That's all they need to think about. And what that means is, let's just imagine for a second, a refrigerator that automatically restocks itself, and you just take out the vaccines, you give it to a child, and you go on your merry way. That's obviously a little bit of an idealistic way of viewing things, but it's the experience that we want to accomplish." #Canid #Vaccinations #Pediatricians #Vaccines #PediatricVaccineManagement   canid.io Download the transcript here  

Alicia Silver, senior director at ADVI Health, highlights the evolving landscape of cell and gene therapy and the need to improve patient access and payment for these treatments. Availability of these therapies for solid tumors and genetic diseases like sickle cell disease is expanding due to the transition from inpatient to outpatient and community settings. The FDA's decision to remove REMS requirements for specific therapies has accelerated the growth of facilities to provide care, particularly for vulnerable populations. Alicia explains, "We work with a number of different cell and gene therapy clients throughout the sector. So we work with manufacturers who have commercialized cell and gene therapy products. So they have products that are currently on the market, manufacturers who are going through the process of clinical trials right now, working with the FDA to get approved products. But we also work with trade organizations that are working behind the scenes at the sector level, trying to get different policies and access changes for patients."   "To date, there's probably close to a couple of dozen FDA-approved cell and gene therapies, and they treat everything from blood cancers, which were the first approvals in something called CAR T. We saw blood cancers as the first approvals, and then everything through to solid tumors in oncology. But also, we have newer gene therapies for conditions like sickle cell disease. And that's an area that's been incredibly underserved and definitely will benefit from a durable gene therapy that hopefully corrects some of the issues that patients with sickle cell disease have, like pain crises that end up in a hospital. So from that perspective, we see a really wide range of treatments available to patients today and many more on the horizon." "I think the price tag is definitely somewhat of sticker shock for people who don't understand how cell and gene therapy products are valued. And so what we do a lot of times, educating on, is helping payers understand that it's not necessarily $2 million for a treatment that's going to be a recurrent payment, but something that's kind of an investment in the patient's and the plan's future." #ADVIHealth #CellTherapy #GeneTherapy #AcesstoCellGeneTherapy #ClinicalTrials  advi.com Download the transcript here

Dr. Stacy Lindborg, President and CEO of IMUNON, has developed a DNA-based immunotherapy candidate for the treatment of ovarian cancer. This therapy works by administering the drug, which utilizes IL-12, a powerful anti-cancer cytokine, directly into the cavity where the cancer resides, thereby affecting the tumor microenvironment. Trials are showing that the drug can produce significant life extension when used in combination with standard chemotherapy. Stacy explains, "There are about 300,000 women who are newly diagnosed with advanced ovarian cancer every year, about 20,000 in the US, and the frontline standard of care hasn't seen a change in the treatment in about 25 years. So this is for newly diagnosed women. The very first treatment that they would have, which we call frontline treatment, is a platinum-based chemotherapy. So carboplatin and Paclitaxel are both administered through IV over an hour for carboplatin, about three hours for Paclitaxel. So most women go directly to chemotherapy and then surgery, and then chemotherapy. Some women will go straight to surgery and then have this chemotherapy afterwards."   "Our approach is a DNA-based immunotherapy candidate that we have in Phase 3. We refer to the lead candidate as IMNN-001, and this is a non-viral nanoparticle that is administered directly into the cavity of interest. So, what we call the micro-tumor environment is the peritoneal cavity, where the cancer actually resides, and it's delivered through a catheter. And it basically has a very powerful anti-cancer fighting cytokine, IL-12, that is encoded in this immunotherapy. And it causes the cells that are within each woman's body, both cancer and non-cancer alike, to start producing activities that will help fight these complex cancer cells that exist."  #IMUNON #OvarianCancer #DNABasedImmunotherapy #WomensHealth #CancerAwareness  imunon.com Download the transcript here

Donovan Campbell, CEO of Medbridge, empowers clinicians through a platform that is focused on movement-based medicine and a holistic approach to patient care. MedBridge has developed AI tools to perform triage, act as a care coordinator, and serve as a patient-facing coach, offloading administrative tasks and providing better support to patients. These tools are designed to support clinicians by flagging potential issues and increasing patient engagement by delivering immediate digital access to care.  Donovan explains, "We serve primarily physical therapists. And those physical therapists can work either in what's called a private practice outpatient setting or in a hospital setting, whether that's inpatient rehab or outpatient rehab. We also service physical therapy and adjacent practitioners, such as athletic trainers, speech and language pathologists, or occupational therapists. With the release of our new hybrid care platform, we're moving into different care categories, which is really exciting. So we're increasingly working with advanced primary care companies that service the employer health market. That's exciting. And we're exploring other opportunities within women's health and within orthopedics."   "Movement-based medicine is relevant to a really holistic approach to patient care, and it spans multiple clinical specialties. So think about the elderly patient who's just had a right knee replacement. Movement-based medicine is critical to getting them back up and on their feet. For a woman postpartum, pelvic health and movement-based medicine are really important. And pelvic health, movement-based medicine that she can access at home, is really important in her recovery and meeting her where she's at in her phase of life. And then physical therapy obviously is all about movement-based medicine."   #Medbridge #DigitalHealth #HealthcareAI #FutureAI #MovementBasedMedicine medbridge.com Download the transcript here

Dr. Matt Goldstein, CEO of jscreen, focuses on the importance and power of preventive genetic testing for reproductive carrier screening and hereditary cancer screening. All genetic tests include analysis to inform specific medical management plans and provide genetic counselors to explore options. Of particular interest is testing for the gene mutations that cause Tay-Sachs disease and helping families take proactive steps to effectively eliminate the disease in future generations. Matt explains, "So, jscreen is a nonprofit that focuses on providing access to education and high-touch support to individuals, families, and to clinicians in the area of preventive genetics and more specifically for reproductive carrier screening and hereditary cancer screening. "These types of tests actually have been around for a really long time with the advancement in genomic technology and our knowledge generally of genetics. The capabilities we have around these panels—what we can test for and what we can do with them—have grown tremendously over the last two decades. And so, what we're offering now is completely different than what you may have been offered five or 10 years ago." "What I will say is I think that this technology is the most powerful medical intervention that we have. Maybe second to vaccines, which we know obviously can have profound impacts on saving lives, preventive genetics, the ability to screen an individual or a couple or a family, and identify diseases that they may be at risk for, with things that you can do to prevent those diseases from happening or catch them early. That's the holy grail. That's the most amazing thing: being able to intervene."  #jscreen #GeneticTesting #TaySachsDisease #ReproductiveCarrierScreening #HereditaryCancerScreening  jscreen.org Download the transcript here

Dr. Yuri Maricich, Chief Medical Officer at CAMP4 Therapeutics, describes regulatory RNA, a new area of biology that recognizes the role of Reg RNA in the production of proteins from specific genes. This technology is well-suited for haploinsufficient diseases such as SYNGAP1-related disorders, in which there is a lack of healthy protein and both parents carry a copy of the mutated gene. The goal is to create disease-modifying treatments that correct the underlying genetic cause rather than treating the symptoms. Yuri explains, "What was really unique about CAMP4's scientific approach is that we're focused on a whole new and emerging area of biology called regulatory RNA. And these are control elements for the expression of genes. In other words, how much protein we get from a particular gene. And there's been a lot of work in the past on how to have less protein made, particularly if it's a protein that has a mutation that causes a problem. But in medicine, there have been very few opportunities to actually increase the amount of protein, but there are many diseases that need more healthy protein."  "The backdrop of CAMP4 is that there was work done just over eight years ago at the Whitehead Institute at the Massachusetts Institute of Technology in a lab by Rick Young, and he was working with a colleague at Boston Children's Hospital, Lenson, and they noticed that there was this group of so-called regRNAs. These were non-coding regions that historically have been really ignored. And as they looked and explored their function further, what they discovered was that, in fact, these regRNA elements play a critical role in controlling how much protein is produced. And so the story of CAMP4 has been to continue to understand and map different cell lines so that we could take a particular target gene and, by using tools or established medicines, for example, like antisense oligonucleotides, we could actually increase the amount of a gene's protein back up to normal." #CAMP4 #CAMP4Therapeutics #SYNGAP1 #CuresSYNGAP1 #regRNA #RegulatoryRNA camp4tx.com Download the transcript here

Phil L'Huillier, CEO of Scancell,  has developed an off-the-shelf DNA immunotherapy designed to generate a potent and durable immune response against advanced melanoma in patients who are unresponsive to current therapies. Their lead candidate showed significant benefit when added to standard of care checkpoint inhibitors, improving duration of response without adding side effects or toxicity. Patient selection in future trials will use a blood test to identify the immune types that can be expected to respond best to the therapy. Phil explains, "Perhaps first and foremost, Scancell is a clinical-stage company developing novel active immunotherapies for patients. And our objective for patients is to pick up the patients that are unresponsive to current therapies or that respond for a short period of time to improve the overall survival through developing therapies that give a good duration of response, potent immune responses, but are also safe for patients." "Perhaps before I share results from the studies, I should step back a little bit and just tell you about the platform and the product that the data has arisen for. At Scancell, we're developing these off-the-shelf. The data that we're about to talk about comes from our lead program, which is an off-the-shelf DNA immunotherapy called Immunobody, that's the name that we use for it. And it's different from the personalized therapies, the personalized vaccines that require an individual to give a tumor sample. And then there's sequencing and manufacturing for the individual there. This is off the shelf." #Scancell #Immunobody #Immunotherapy #Cancer #Oncology #Melanoma #Biotech scancell.co.uk Download the transcript here

Dr. Costas Karatzas, CEO, Director, and Co-Founder of Acesis BioMed, is focused on developing a novel treatment for low testosterone in men, an oral peptide that stimulates the body to restore its own natural testosterone production. The therapy's mechanism differs from current testosterone replacement therapies and avoids the side effect of infertility seen in younger men using traditional TRT, which shuts down natural hormone and sperm production. This low T condition is not just a function of aging but is increasingly affecting younger men due to lifestyle, environmental factors, and co-morbidities like diabetes and obesity. Costas explains, "Our mission is to revolutionize the treatment of low T, or male hypogonadism, and related comorbidities. Although we remain laser-focused on going in phase one with a low T application, because low testosterone is involved in many other diseases like type 2 diabetes, fatty liver disease, obesity, etc., we're also going to be co-developing those with partnerships initially with academia and later on with other pharma companies. So this is, in a nutshell, the short story about Acesis. The differentiation being everything else marketed provides the body with exogenous testosterone, whereas in our case, we teach the body to go back to its old memory and generate or restore its own testosterone in a natural way." "Men can develop low testosterone because of the aging process, but this is a wrong idea. Low testosterone is not just an aging problem. It's true that we as men lose testosterone from the age of 30, about 1-1.5%, which is circulating in our blood. By the time we reach sixties or seventies, we could have probably 50% to 60% of the testosterone levels we had while we were at the age of 30 years old. Globally, it's estimated that about 40% of adult men may have suboptimal testosterone levels, especially if you include men with other health issues like diabetes, and we mentioned obesity. So, for older men, this is a big demographic, and as the global male population ages, the number of men with low T is increasing. Interestingly enough, the FDA has only approved the current marketed products of testosterone for men who are between the ages of 30 and 65. Anything over 65 is considered a normal process of aging according to the regulators." #AcesisBioMed #HormoneHealth #TestosteroneReplacementTherapy #TRT #MensHealthAwareness #BiotechInnovation #EndocrinologyResearch #LowT #MensHealth #Testosterone #HormoneResearch #Menswellbeing #Andropause acesisbio.com Download the transcript here

Dr. Adam Rogers, CEO of NervGen Pharma, highlights the significant unmet medical need for treating spinal cord injuries (SCI), as there are currently no approved pharmacological treatments to promote repair.  The science behind this neurotrauma company's drug is designed to interfere with the inhibitory molecules that prevent neurons from regenerating after injury, allowing the nervous system to repair itself. Recent trials have shown success in patients with chronic SCI, indicating that it is possible to promote recovery long after initial damage occurs.. Adam explains, "Our mission at NervGen is to improve the lives of individuals with spinal cord injury. And there are roughly 310,000 individuals with spinal cord injury in the United States, and about 18,000, roughly 18,500 new cases per year. And it's such a difficult injury to treat because, other than largely exercise and physical therapy, there are absolutely no approved pharmacologic treatments that promote functional repair for individuals who have suffered a spinal cord injury."   "I'm a physician by training. I practiced for nearly 20 years, and in the medical world, we have always been taught that when a neuron is damaged, as occurs in spinal cord injury, the neuron becomes dystrophic and cannot regenerate. So the medical community has always believed, and I was taught this and even in my practice, that once you have a damaged neuron, that neuron is dead. The problem that we have to solve here is really twofold. Number one, are neurons still viable after a central nervous system (CNS) injury? And number two, if the neuron is viable, how can we get that neuron to sprout, remyelinate, and regrow so that we can gain some function in the end organ that that neuron is supposed to innervate? NervGen's scientific founder, the late Dr. Jerry Silver, dedicated his entire career to understanding what prevented the central nervous system from repairing itself." #NervGenPharma #SpinalCordInjury #RegenerativeMedicine #NeuroTrauma nervgen.com Download the transcript here

Dr. Sanjay Kakkar, CEO of Tensive, has developed an innovative bioresorbable polymeric scaffold for breast regeneration following a lumpectomy.  The scaffold was designed to address a significant unmet need for breast cancer patients who have limited options for reconstruction. A key feature of this technology is that it facilitates a natural wound-healing response, allowing the body's own vascular, connective, and fat tissues to regrow as the scaffold gradually dissolves. Sanjay explains, "What we've been developing at Tensive is at a late clinical stage of these advanced biomaterials, and we've spent the last decade or so pioneering this bioresorbable polymeric scaffold for natural tissue regeneration. So, coming directly to your question, we're on this mission to provide breast cancer survivors with the option of a natural breast reconstruction. What we developed is this resorbable biopolymer that can be implanted at the time of the lumpectomy procedure." "But what it does is it replaces volume immediately, and it facilitates new tissue growth without cells or growth factors. This sponge, which is made of a fine scaffold matrix, gradually degrades. So it immediately fills the cavity left by the tumor removal. It facilitates natural tissue regeneration, allowing the body's own cells to grow back into the 97% of empty space, which is formed by this sponge. And that basically means that initially vascular tissue regrows inside the porous architecture, then connective tissue, and then fat comes back."  #Tensive #BreastCancer #BreastCancerAwareness #ClinicalTrials #ReconstructiveSurgery #REGENERA #BreastHealth #BreastReconstruction #Lumpectomy #Innovation tensive.com Download the transcript here

Dr. Saria Saccocio, Chief Medical Officer at Essence Healthcare, is using AI to enhance care and services for patients who are enrolled in Medicare Advantage programs. One application is to analyze data related to health equity, care authorization, and to address biases. Their AI agent is being used to interact with patients, offering them the option to access a human. Integration with wearables, such as the Oura Ring, focuses on identifying clinically useful information to prevent physicians from being overwhelmed by data. Saria explains, "Medicare Advantage plans are absolutely that. It's an advantage because of the additional benefits that exist and the opportunity to connect with our members is rather unique. In fact, what I'll share with you and the audience is that AI has been a focus for us and a priority as we continue to expand the focus on quality and engagement with our members so that they have their best quality life possible to them. AI is a major piece of this work to make that happen. I can give you a couple of examples. In fact, when it comes to health equity, CMS has recently required Medicare plans to ensure that we are analyzing our data through a health equity lens. This year, in fact, we're focused on authorizations, authorizations of care. We want to make sure that it is critical to our members and AI. I see an opportunity to recognize any blind spots or implicit bias."   "I think that every human being has a capability for technology. And what's critical is that we meet them where they are, that we understand what they want, what they need out of technology. I think that works as well as providers. As you see all of these AI developers starting up companies and solving problems, the conversation that we're having every day at Lumeris and at Essence Healthcare is what does the patient want? What does that member need for quality of care? And then engage and include the providers in that conversation. What makes their job easier? Because one of the challenges with new technology is that we can also reach a point of technology exhaustion. So I'll give an example of our relationship with Oura ring, the wearable device that tracks for sleep, for health, for heart rate, and a number of different measures."    #EssenceHealthcare #MedicareAdvantage #HealthAI #OuraRing #DigitalHealth essencehealthcare.com Download the transcript here    

Kerry Mello-Parker, Director of Rare Diseases and REMS programs at Shields Health Solutions, addresses the complexities and challenges faced by patients with rare diseases including diagnostic delays and limited access to medication. Using an integrated specialty pharmacy model, Shields works with pharmacists to have direct access to the EHR, enabling better patient monitoring, shorter time to initiate medication, tracking outcomes, and providing patients with a direct line of communication to their care team. Pharmacists treating rare diseases are also supported with specialized information on medication administration, side effects and complex billing.  Kerry explains, "Shields Health Solutions is a specialty pharmacy accelerator. We partner with over 80 health systems across the United States. We support them in establishing and growing a specialty pharmacy. We help them to access critical medications. Some of them are not available at traditional pharmacies, and we support them in managing clinical quality care programs for their patients." "I'd like to step back a little and talk about what a rare disease is and how we define it. Currently, it is defined as a condition that affects fewer than 200,000 people. However, over 7,000 rare diseases exist. So when we do the math, we come to see that they are not so rare. And some estimates show that up to 10% of the US population may actually have a rare disease. And what I've seen is that there are really three main complexities of treating rare diseases and challenges that patients may face. One of them is that there is a lack of available treatment options when compared with more common diseases. So, for example, only about 10% of rare diseases have an FDA-approved treatment option, but that is changing. We have the Orphan Drug Act, which has actually changed the landscape. It has incentivized and facilitated the development of medications to treat rare diseases." #ShieldsHealthSolutions #IntegratedCareModel #SpecialtyPharmacy #RareDiseases #MedicationAdherence shieldshealthsolutions.com Download the transcript here

Ram Sahasranam, President and Co-Founder of Fold Health, has created a platform that integrates with the EHR to create an AI-driven interface that streamlines workflows, improves communication across the care team, and helps better manage patient care. Traditional EHR systems, while effective for documentation, were not built for proactive care and data sharing. With a focus on the patient and providers, Fold Health is integrating data sources and automating redundant administrative tasks helping to reduce clinician burnout and improve patient communication for scheduling and reminders. Ram explains, "The way to look at it is that empowering providers and patients need to go hand in hand. That is the fundamental reason why we called ourselves Fold Health, which is that healthcare needs to fold around the providers and the team supporting the providers and the patients and the families of the patients who are involved in the care. We have seen healthcare go from $1.6 trillion in spending to $5.3 trillion in spending this year. But in those 15 years, we haven't yet seen it fold around the two most important people, the provider or the patient, in terms of better outcomes or improving the burnout rates that clinicians and their teams face today." "So the fundamental challenge that we noticed was that multiple people were living in different systems and hence different silos from a data standpoint. So the clinician did not know what was happening with their care teams. The patient was living in a different system. If the patient goes to a specialist, the data comes in a compressed format to the physician in an easily digestible manner, which was a challenge. So what Fold does as a result of getting control of all these different nodes is that data can be used to summarize and provide things for the different teams in a quick, easily digestible manner."  #Foldhealth #CareCoordination #CareDelivery #ConnectedCare #HealthTech #AI #HealthAI Fold.Health Download the transcript here

Ralph Keiser, CEO of ArcheHealth, highlights the severe financial pressures that hospitals are confronting as a result of rising costs and declining reimbursements. Reductions in reimbursements are threatening hospitals that serve underinsured populations. Costs are increasing due to tariffs on medical device components and the general price inflation on medical supplies and drugs.  ArcheHealth is focused on helping hospitals improve operational efficiency to lower the expense of delivering care. Ralph explains, "The tariff index is going to come mostly around medical devices and device components. So plastics, metals, packaging, things that the device manufacturers use to deliver their products to hospitals and health systems, those will likely get passed through. It won't be huge incremental costs, so there will be additional costs due to tariffs. It depends on a couple of things. Do you have a strong contract that sort of embargoes your current price? Then maybe in the next contract term you'll see that pass through or the contract so the supplier to pass through, you'll see them. We're monitoring month by month the current or last month's spend was on these items, and do we see a chart impact by manufacturer by line." "One thing that I want to make sure we talk about, too, isn't just shared impact. So the cost to a hospital for devices and drugs averaged 8.9% more in 2024. So just by nature of the market raising its prices for goods that hospitals use to cover patient care, those moved up without tariffs 8.9% last year. We think we're tracking increases that are happening despite the tariff overlay or on top of the tariffs. We still think that the pressure on hospitals is due to the price of therapeutics, and is going to continue to go up, tariff or not. And so I want to mention that because this is the ongoing impact of the cost of MedTech and drugs that gets passed through to the consumer." #ArcheHealth #AIinHealthcare #HealthTech #HealthcareOperations archehealth.ai Download the transcript here

Dr. Marc Salzberg, President, CEO, and Chief Medical Officer at Airway Therapeutics, is developing a drug AT-100 to prevent bronchopulmonary dysplasia (BPD) in preterm infants, a severe condition with no existing treatment. These infants are at high risk for BPD because of a low level of a protective protein that reduces inflammation and clears infections from their underdeveloped lungs. The drug's mechanism of action suggests it has potential for treating other inflammatory conditions such as asthma, COPD, and severe pneumonia. Marc explains, "We're focusing on developing drugs or interventions for severe respiratory conditions for prevention or treatment of severe respiratory conditions. And our first project is focusing on the respiratory condition that preterm neonates have, which is called bronchopulmonary dysplasia, and cannot be treated or prevented yet. It's a very severe condition. And that really triggered my interest in getting engaged because it's going to be a paradigm shift if we manage to bring this drug to market." "The protein that we're developing is an endogenous protein that we all have. In the past years or decade, it has been discovered that this protein has a very essential function in fighting inflammation and infection on a daily basis. Now, there are certain conditions or instances where the protein is low-functioning. For instance, in preterm-born babies, but also in adults with severe respiratory inflammation, with pneumonias, with asthma, or COPD. In all those cases where protein is low, those are the instances where you actually need it most. So, replacing it in those instances is a kind of logical rationale for the concept for the treatment that we're developing." #AirwayTherapeutics #BPD #InflammatoryDiseases #Zelpultidealfa #PrematureBabies #PretermBabies airwaytherapeutics.com Download the transcript here  

 Wade Demmer, R&D Vice President at Medtronic, has developed a leadless pacemaker that is implanted on the heart through a minimally invasive procedure utilizing a catheter, potentially creating fewer complications and greater access for patients who could benefit from a pacemaker. This new design is a significantly smaller, safer, and longer-lasting device than traditional pacemakers and does not create a visible lump under the skin. Advancements in battery and computer technology have made the Micra next-generation pacemaker smarter, allowing cardiologists to treat a wider range of heart conditions. Wase explains, "So yes, pacemakers have been around for about seventy years. They've been helping people save lives, live fuller lives, and improve quality of life for that whole time. But you know, if you think about the history of a pacemaker, a pacemaker is a computer inside a little box that's implanted in the body. And like any computer, a computer from 70 years ago and a computer from today are very different. You know, 70 years ago, a pacemaker would've been about the size of a hockey puck, but even a little bit thicker. And nowadays, pacemakers are not much bigger than a couple of silver dollars stacked together. So we've made really big advances."   "When you had those hockey puck-sized pacemakers or even modern-sized pacemakers, there's no place in the heart for it. And so they end up in the chest, and then there's a wire called the lead that goes down through the veins into the heart, and that's where the electricity gets delivered down to make the heartbeat. And that's also where the heart's electricity comes back up, so the pacemaker can know what's wrong. As we have pacemakers smaller and smaller, though, we suddenly reach a point where a radical downsizing is a possibility. And again, leveraging the computer technology of the world, getting a pacemaker inside the heart instead of in the chest."   #Medtronic #CardiacCare #Pacemaker #LeadlessPacemaker #Micra #Cardiologists #HeartHealth #Innovation medtronic.com Download the transcript here   

Dr. Vishwa Srivastava, APAC CEO of SSI, SS Innovations International, is a leader in telesurgery, using robotic surgery to extend surgical services in underserved areas. The SSI Mantra surgical robot is used for laparoscopic surgery and offers an affordable alternative to prevailing robotic solutions without compromising quality. Telesurgery has potential in remote operations and is also revolutionizing surgical training by providing real-time expert proctoring. Vishwa explains, "My father was one of the early global pioneers in robotic cardiac surgery, and he had actually helped Intuitive Surgical back in their early days get their FDA approval. And what he recognized very quickly was that through these minimally invasive robotic cardiac surgical procedures, 20% of his patients went home the next day, 50% in two days or less, and the average length of stay was 3.2 days. So, he became convinced after they twisted his arm to launch robotic cardiac surgical programs. And Dr. Fred Moll at the time was the chairman and founder of Intuitive Surgical, and he wanted to start on the heart because it was the most complex procedure to do a beating heart, totally endoscopic, bypass surgery. And he felt that if you could do that, then everything else would be simple."   "The way that we look at remote robotic surgery, or what we call telesurgery, currently, we are the only company in India that has received formal regulatory approval from the CDSCO for both teleproctoring and telesurgery. The way that we look at teleproctoring and telesurgery, it's not like one rockstar surgeon sitting in one location operating omnipresent in a hundred different locations." "With teleproctoring and telesurgery, the way that we look at it is in addition to operating and extending expertise in the remote areas of the country, we look at teleproctoring and telesurgery the same way that doctors are trained in residency where you always have an attending in the room, the junior surgeon will be operating, and the goal of the proctor or the attending surgeon is to guide the junior surgeon to maturity."  #SSInnovations #RoboticSurgery #Telesurgery #CardiacProcedures #HeartSurgery #Teleproctoring #RemoteSurgery  SSInnovations.com Download the transcript here

Vikram Ahuja, Co-Founder and CEO, and Joe Promoppatam, Co-Founder and CTO of OsseoLabs, are utilizing 3D printing and AI to advance reconstructive surgery by enabling the creation of personalized, precision-fit implants and surgical instruments. Traditional surgery has relied on standardized implants made of titanium and involves lengthy operations. The OsseoLabs approach reduces surgical planning and operating time, improving patient outcomes by achieving a better fit and enhanced bone integration through the use of advanced implant materials. AI is used to automate and accelerate the design process for these custom devices, enabling a scalable and cost-effective approach to create complex, regulated medical devices. Vikram explains, "We want to use our engineering know-how, especially in 3D printing, to improve the quality of the outcome of the surgeries and also help the students to be able to offer a better solution at a speed, and also the outcome that is a little bit more precise. And that's what we have been working on for quite a long time. We want to use the knowledge of 3D printing, biomechanics, and also AI to help, especially in complex surgical cases. So both the patients and the surgeons are better off with the outcome. And the main gap that we are seeing here is not only in the Asian countries where we operate, but also in the US. And the use of 3D presented implants, even though it has been around for quite some time in the US, we still see a lot of gaps that can be improved in what materials are being used, and how the implants are designed. We help the surgeons and also the hospitals throughout this process." Joe elaborates, "Yes, for such a device, they all look the same way, but the patients look different. So we see this gap between the available instrumentation and the actual treatment that the surgeons want to conduct. And we want to break that barrier by being able to decide which instrument is required individually, and I mean that in the day, we could not do that. The price can be competitive because all the manufacturing technology is used to support production. But we have to depend on how they matured in the past few years. We are able to adopt the technology, which allows us to decide and print the instrument for specific care and specific surgery. I think the speed and cost become much more practical, and all we need to look into is the 3D printer. But eventually, when you come into something like customization, you talk about the speed. In terms of speed, it's not just the speed of how we make things, but it's about the speed of how we decide things. That's where we see the gap that we can fill using AI to split up the bedside process."   #OsseoLabs #ReconstructiveSurgery #3DPrinting #PersonalizedImplants #MedAI OsseoLabs.com Download the transcript here

Trân Lê, Co-Founder and CEO of Grove AI,  was founded to automate the manual and inefficient workflows in clinical trial recruitment, patient engagement, and support. The company's AI agent, Grace, is trained on specific trial protocols and approved scripts to respond to patient questions about pre-screening, logistics, and scheduling appointments. This platform aims to increase speed and quality of participant recruitment, improve representation, and expand accessibility to clinical trials by offering support in over 19 languages and providing access to information on demand. Trân explains, "The birth of Grove really came from my co-founder, Sohit, and his experience working in the hospital. We were working at Stanford, and there we were, computer scientists building a lot of internal tools for clinical trials, clinical research, as well as for the greater healthcare patient services. And that, combined with my experience trying to enroll in a clinical trial, really set us off to think deeply about how we can automate a lot of the manual workflows that exist today for patients and for providers, as well as for pharma in taking new drugs to market. Specifically, within that, we identified patient engagement and support, and prescreening to be an important part of ensuring that patients know where they're going and what to do when they're participating in these trials. And so we decided to really step out into the industry and change this process and make it an easier and more accessible experience for patients."   "I would say that having worked inside a hospital and seeing all of this lead generation or getting people educated about the trial is an important aspect, and it's being done by a lot of the recruitment vendors as well as in-house teams out there. In addition to that, a bottleneck that previously has always been there now is possible to automate with agentic AI is actually doing the work of taking all the interest from different potential patients and helping them prescreen and understand the requirements of the trials, getting them to the right site, booking their transportation, reminding them about the appointments, and scheduling that appointment."   "I would say that Grace, as we call her, is a digital staff or an AI agent - both are comparable terms to describe Grace. The difference is that Grace is trained on the trial, the requirements, and the IRB-approved script of that trial. So she really has the knowledge to be able to respond spontaneously in real time to any questions that the participant may have about the trial." #GroveAI #ClinicalTrials #PatientRecruitment #Pharma #HealthTech #DigitalHealth #AI #AgenticAI grovetrials.com Download the transcript here